Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development and Validation of an Anoikis-Related Machine Learning Signature for Prognosis and Brain Metastasis-Associated Classification in Lung Adenocarcinoma.

Cancers·2026

Same author

Comment on "A prognostic microRNA-based signature for localized clear cell renal cell carcinoma: the Bio-miR study".

British journal of cancer·2026

Same author

FGFR Aberrations in Solid Tumors: Mechanistic Insights and Clinical Translation of Targeted Therapies.

Cancers·2026

Same author

Correction: Immune cell communication networks and memory CD8+ T cell signatures sustaining chronic inflammation in COVID-19 and Long COVID.

Frontiers in immunology·2025

Same author

Adhesion of Immunoglobulins to Band3 Promotes Increased Erythrocyte Sedimentation Rate in Multiple Myeloma.

Cell proliferation·2025

Same author

Immune cell communication networks and memory CD8<sup>+</sup> T cell signatures sustaining chronic inflammation in COVID-19 and Long COVID.

Frontiers in immunology·2025

Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026

Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026

Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026

Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026

Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026

Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 10, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Bridging Discovery and Treatment: Cancer Biomarker.

Hengrui Liu¹, Ilayda Karsidag², Rebecca Golin³

¹Department of Biochemistry, University of Cambridge, Cambridge CB2 1QW, UK.

|November 27, 2025

Summary

This summary is machine-generated.

Biomarkers are revolutionizing cancer care by enabling personalized treatments. This review covers detection methods, translational challenges, and AI-driven solutions to improve patient outcomes and overcome tumor heterogeneity.

Keywords:

cancer biomarkers multi-omics technologies personalized medicine precision oncology translational research tumor heterogeneity

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Related Experiment Videos

Last Updated: Jan 10, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Area of Science:

Oncology
Biomarker Discovery
Personalized Medicine

Background:

Biomarkers have significantly advanced cancer care by connecting molecular information with tailored treatment approaches.
The integration of diverse detection modalities is crucial for comprehensive cancer profiling.

Purpose of the Study:

To review the current landscape of cancer biomarker detection modalities.
To critically assess the challenges hindering the clinical implementation of biomarkers.
To explore emerging solutions and future directions for biomarker development and application.

Main Methods:

Comprehensive literature review of biomarker detection techniques.
Analysis of translational challenges in clinical implementation.
Exploration of emerging technologies and future research directions.

Main Results:

A wide spectrum of detection modalities exists, including tissue genomics, liquid biopsies (ctDNA, CTCs, extracellular vesicles), imaging/radiomics, and multi-omics.
Significant translational challenges impede clinical use, such as assay standardization, data integration, validation, regulatory hurdles, and cost.
Emerging solutions like AI-driven phenotyping, adaptive trials, and point-of-care assays show promise.

Conclusions:

Biomarkers are pivotal in guiding targeted and immune-based therapies.
Addressing translational challenges and leveraging new technologies can overcome tumor heterogeneity and resistance.
Expanding access and equitable adoption of biomarker-guided cancer care is essential for improving patient outcomes.